Can CytomX’s Probody checkpoint beat the competition?

Can we improve on the tolerability of the nivolumab-ipilimumab regimen by designing better a checkpoint inhibitor?

November 5, 2018

What did we learn from Neon at ESMO18?

Initial results from the neon NEO-PV-01 phase 1B trial presented by Dr Patrick Ott

October 30, 2018

Is blood TMB ready for prime time?

With new data on the blood-based TMB test at ESMO, what can we learn about this approach?

October 29, 2018

Why are the SOLO1 data so compelling?

A discussion about the impact of the olaparib on the PARPi niche based on the findings of the SOLO1 trial

October 26, 2018

5 Trends from ESMO18

New trends in early drug develoment and Developmental Therapeutics

October 24, 2018

ESMO18 Live Blog Day 4

Wins for Pharma, some shakeouts for small biotechs on manic Monday at #ESMO18

October 22, 2018

ESMO18 Live Blog Day 3

Highlights and lowlights from Munich

October 21, 2018

ESMO18 Live Blog Day 2

Highlights and lowlights from Day 2 of #ESMO18

October 20, 2018

ESMO18 Live Blog Day 1

Highlights from Day 1 of #ESMO18 in Munich

October 19, 2018

ESMO18 Preview 5 – A look at the evolving Renal Cell Carcinoma landscape

The changing face of renal cell cancer from several perspectives

October 16, 2018

ESMO18 Preview 4 Gems from the Poster Halls

A dozen poster abstracts to watch out for at ESMO18 on a wide range of topics...

October 11, 2018

ESMO18 Preview 3 Top 10 Oral Abstracts

Third ESMO18 preview on oral abstract presentations

October 8, 2018

New developments in neoantigen vaccines

A look a progress on NeoVax in GBM, RNA vaccines and even a novel CAR T cell therapy with a difference.

October 8, 2018

ESMO18 Preview 1 Late Breakers What To Watch Out For

ESMO18 Preview 1 - Late Breaking Abstracts to watch out for

September 26, 2018